|
|   |
Home (12954 companies) > France (2162 companies) > Pharmaceuticals (35 companies) >
Aventis SA
| shareholder | country  % source |
|
| subsidiary | country  % source |
|
|
name  items photo compare the prices |
Shop local, ethical and at the best price on Ethishop ! |
|
|
|
|
| Job: 4% of company's jobs cut since 1998 |
| Environment: 4 major pollution(s) |
| Delinquency: 12 act(s) of financial or trade delinquency |
| Tax haven, secret bank account, shell companies: operates in 3 offshore financial center(s) |
| Sales: more than 25 billion(s) dollars/euros in annual sales |
| Net profit: more than 4 billion(s) dollars/euros in cumulated net profit since 1998 |
| Top management: earns 806 times the median income in the United States (32000 US$/year) |
| Influence: 10 act(s) of direct corruption or lobbying |
| Advertising & marketing: 3 dubious practice(s) |
|
|
World locations & Manufacturing |
country incentive : address & contact : production type source |
|
year name | photo position; compensation source |
| 2002Landau, Igor |  Chairman of the Executive committee; salary: 2 million Eu€; stock-options: 8 million Eu€; |
| 2001Dormann, Jurgen |  Chairman of the Executive committee; salary: 2.35 million Eu€; stock-options: 14.87 million Eu€; |
| 1999Dormann, Jurgen |  Chairman of the Executive committee; stock-options: 0.35 million shares; |
|
|
year | employees <> | social impact : country source |
| 2002 | 91729 | |  |
|
year | country : consequences source |
| 2000 | : Production, purchase or sale of genetically modified organisms which may cause an irreversible genetic pollution, a destruction of the biodiversity and health risks for the consumers. |  |
|
year | purpose : intermediary/lobby : institution source |
| 2002 | Market admission for genetically modified organisms : Europabio : : European Commission translate | Corporate .  |
| 2000 | Prevent binding environmental regulations (environmental protection through economic growth, self-regulation and free trade) : WBCSD (World Business Council for Sustainable Development) : : United Nations translate | Corporate .  |
| 2000 | Limit the legal liability, no price control, no list of preferred drugs, hampers the approval and marketing of generic drugs, no drug imports, no limit to drug advertising… : Pharmaceutical Research and Manufacturers of America : : US government, congress, senate translate | Washington.  |
| 2000 | Market access (through WTO), cheaper energy (through energy liberalization in Europe); uniform rules to enable the patenting of plants and animals (through TRIPS); prevent advert legislation on chemicals, self-regulation instead; : CEFIC (European Chemical Industry Council) : : European Commission translate | Corporate .  |
| 2000 | Lift the ban on bovine growth hormons, the moratorium on GMOs : EFPIA (European Federation of Pharmaceutical Industry Associations) : : European Commission translate | EFPIA  |
| 2000 | Access to public services (privatization through GATS) : ERT (European Roundtable of Industrialists) : : European Commission translate | Corporate .  |
|
year | financial misdemeanor | sales | income | | buyback | source |
| 2007 |
The laboratories Roche, BASF and Aventis were fined 8,5 million dollars in Brazil. They were accused of having formed a cartel, price agreements, market sharing and unfair competition on the market of vitamins. During second half of the Nineties, these three companies would have restricted the offer and increased the prices of the vitamins A, B2, B5 and C They would have also prevented the entry on the market of less expensive Chinese vitamins. |
| | | |   | |  |
| 2006 |
Roche Holdings AG, BASF AG and Aventis will pay 30.5 mln usd to settle an Australian class action alleging they organised a cartel to fix the price of vitamins. The applicants in the class action, many of whom were farmers, alleged that as a result of the cartel they lost market share or paid inflated prices. |
| | | |   | | AFX  |
| 2005 |
Sued by the State of California for defrauding the state's $34 billion Medi-Cal program by inflating prices. "We're going to drag these drug companies into courts of law because they've been gouging the public," California Attorney General Bill Lockyer said at a news conference. For example, Medi-Cal paid $804.70 US for a bottle of the hypertension drug Atenolol. Providers such as doctors, clinics and pharmacists paid $33.85 US. As a result, providers reimbursed by Medi-Cal for Atenolol pocketed $770.85 US. The windfalls gave doctors, pharmacies and other providers an incentive to prescribe such drugs, which resulted in even more sales by drug makers, Lockyer said. |
| | | |   | | Canadian P.  |
| 2003 |
| | 1.9 | |   | billion Eu€ |  |
| 2003 |
Entente sur le prix de la methionine sur le marché états-unien. Aventis verse 178 M$ pour mettre fin aux poursuites. |
| | | |   | |  |
| 2003 |
Entente illicite; accord entre Aventis et Andrx pour qu'Andrx ne vende pas son médicament pour le coeur Cardizem à un prix inférieur à celui d'Aventis: amende de 80 et 110 millions de $US. |
| | | |   | |  |
| 2002 |
| 21.66 | 2.28 | |   | billion US$ |  |
| 2002 |
Entente pour fixer le prix de la méthylglucamine entre 1990 et 1999: amende de 2,85 millions d'euros après réduction de 40% pour avoir collaboré lors de l'enquête. |
| | | |   | | Les Echos  |
| 2002 |
Accused with fraud and bribery schemes to inflate prices for consumers and government health plans. |
| | | |   | | Financial .  |
| 2002 |
market-sharing and price-fixing cartels affecting vitamin products in Europe: 5,04 million euros fine. |
| | | |   | | Commission.  |
| 2002 |
Entente sur le prix de la méthionine, échappe à l'amende pour avoir révélé cette entente. |
| | | |   | | Les Echos  |
| 2001 |
| 20.45 | 1.46 | |   | billion US$ |  |
| 2000 |
| 22.3 | 1.13 | |   | billion Eu€ |  |
| 1999 |
| 12.6 | -0.97 | |   | billion Eu€ |  |
|
|
|
|
Also announce a documentary, a book or an article or comment this company profile.
Goal: present the company activities, improve the ethical rating's accuracy, develop an network of observers.